Trial Profile

A Phase 1b clinical trial of ATR-04 in cancer patients undergoing EGFRi targeted therapy

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 May 2024 According to a Azitra media release, a pre-IND meeting with the FDA for ATR-04 has been successfully completed and planning for track for IND submission mid-2024.
19 Mar 2024 New trial record
15 Mar 2024 According to a Azitra media release, company intend to submit an IND for a Phase 1b clinical trial in cancer patients undergoing EGFRi targeted therapy in mid-2024. Subject to FDA clearance of IND, company plan to initiate a Phase 1b clinical trial by year end. First patient dosing expected in late 2024 or early 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com